Shares of Evotec SE (OTCMKTS:EVTCY - Get Free Report) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $4.13 and traded as low as $3.64. Evotec shares last traded at $3.69, with a volume of 377,337 shares trading hands.
Evotec Stock Performance
The stock's 50 day moving average price is $4.11 and its 200 day moving average price is $4.00. The company has a current ratio of 2.57, a quick ratio of 2.50 and a debt-to-equity ratio of 0.53. The firm has a market cap of $1.41 billion, a PE ratio of 10.39 and a beta of 0.98.
Evotec Company Profile
(
Get Free Report)
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access